RecruitingNot ApplicableNCT02655302

Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD


Sponsor

University Hospital, Lille

Enrollment

100 participants

Start Date

Jul 4, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

Chronic obstructive pulmonary disease (COPD) is a worldwide chronic inflammatory disease of the airways linked to environmental exposure. The chronic course of COPD is often interrupted by acute exacerbations which have a major impact on the morbidity and mortality of COPD patients. A bacterial etiology for these exacerbations is common (almost 50%). Moreover, airway bacterial colonization linked to an increased susceptibility is observed in COPD patients. Effective Th17 immune response is needed to develop a good response against bacteria. Thus, this study aims to demonstrate that there is a defective IL-17/ IL-22 response to bacteria in COPD leading to airway bacterial colonization and infection.


Eligibility

Min Age: 40 Years

Inclusion Criteria3

  • Diagnosed COPD according GOLD guidelines
  • Current or ex-smoker (at least 10 pack-years)
  • Hospitalized for COPD exacerbation

Exclusion Criteria8

  • Asthma or Cystic fibrosis
  • No other chronic lung disease
  • Solid Tumor unhealed or not considered in remission
  • Inhaled drug consumption
  • Women of childbearing potential without effective contraception
  • Pregnant or breastfeeding women
  • Incapable of consent
  • Lack of social security coverage

Interventions

OTHERSample collecting

Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.

OTHERLung function measure

Measure lung function and follow it during 4 years


Locations(4)

University hospital of Lille

Lille, France

Roubaix hospital

Roubaix, France

Seclin hospital

Seclin, France

Tourcoing hospital

Tourcoing, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02655302


Related Trials